Zhang, Ruiwen

MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy

Rayburn, E., Zhang, R., He, J., & Wang, H. (2005) · Current Cancer Drug Targets

Cancer-related Molecular PathwaysCancer Mechanisms and Therapy

Cited by 265

Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies

Agrawal, S., Jiang, Z., Zhao, Q., Shaw, D., Cai, Q., Roskey, A., Channavajjala, L., Saxinger, C., & Zhang, R. (1997) · Proceedings of the National Academy of Sciences

DNA and Nucleic Acid ChemistryRNA Interference and Gene Delivery

Cited by 226

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis

LaCasse, E. C., Cherton-Horvat, G. G., Hewitt, K. E., Jerome, L. J., Morris, S. J., Kandimalla, E. R., Yu, D., Wang, H., Wang, W., Zhang, R., et al. (2006) · Clinical Cancer Research

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 128

Massively parallel feature selection: an approach based on variance preservation

Zhao, Z., Zhang, R., Cox, J., Duling, D., & Sarle, W. (2013) · Machine Learning

Statistical Methods and InferenceCloud Computing and Resource Management

Cited by 85

Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed‐backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms

Wang, H., Yu, D., Agrawal, S., & Zhang, R. (2003) · The Prostate

Cancer-related Molecular PathwaysProstate Cancer Treatment and Research

Cited by 78